This company listing is no longer active
이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!
Albireo Pharma 배당금
배당금 기준 확인 0/6
주요 정보
n/a
배당 수익률
n/a
지급 비율
업계 평균 수익률 | 2.8% |
다음 배당금 지급일 | n/a |
전 배당일 | n/a |
주당 배당금 | n/a |
주당 순이익 | -US$6.29 |
3년 후 배당 수익률 예측 | n/a |
최근 배당금 업데이트
업데이트 없음
Recent updates
We're Hopeful That Albireo Pharma (NASDAQ:ALBO) Will Use Its Cash Wisely
Jan 02Rock star Growth Puts Albireo Pharma (NASDAQ:ALBO) In A Position To Use Debt
Oct 25Albireo Pharma achieves positive phase 3 top-line results of Bylvay in Alagille syndrome
Oct 11Albireo Pharma: Assessing The Sagard Deal
Oct 03Albireo gains on royalty agreement for pruritus therapy
Sep 22Albireo gets reimbursed access to liver disease drug Bylvay in Italy
Sep 06These Analysts Just Made A Significant Downgrade To Their Albireo Pharma, Inc. (NASDAQ:ALBO) EPS Forecasts
Aug 23Albireo Pharma GAAP EPS of -$2.04, revenue of $8.2M
Aug 15Albireo: The Commercialization Of Bylvay Is The Key To A Fair Valuation
Jul 22Despite Lacking Profits Albireo Pharma (NASDAQ:ALBO) Seems To Be On Top Of Its Debt
May 10Albireo: A Speculative Play With Upside
May 03Is Albireo Pharma (NASDAQ:ALBO) Using Debt Sensibly?
Feb 02Albireo: Successful And Accelerating Global Launch Drives Sales Revenue
Jan 31Albireo: Reasons For A Successful Transformation Into A Commercial Company
Nov 24Albireo Pharma: A Post Approval Assessment
Aug 09Albireo reports expanded data on Bylvay and A3907 at EASL international liver congress
Jun 21Some Shareholders May find It Hard To Increase Albireo Pharma, Inc.'s (NASDAQ:ALBO) CEO Compensation This Year
Jun 11Why Albireo Must Be Valued Higher Than Its Competitor Based On The Value Of Odevixibat
Apr 26Industry Analysts Just Made A Substantial Upgrade To Their Albireo Pharma, Inc. (NASDAQ:ALBO) Revenue Forecasts
Feb 27Albireo launches late-stage trial of odevixibat in Alagille Syndrome
Dec 17Albireo submits U.S. and European applications for odevixibat in liver disease
Dec 09Albireo Pharma (ALBO) Investor Presentation - Slideshow
Nov 17Albireo Pharma's odevixibat shows durable response in a rare pediatric liver disease
Nov 13결제의 안정성과 성장
배당금 데이터 가져오기
안정적인 배당: Insufficient data to determine if ALBO's dividends per share have been stable in the past.
배당금 증가: Insufficient data to determine if ALBO's dividend payments have been increasing.
시장 대비 배당 수익률
Albireo Pharma 시장 대비 배당 수익률 |
---|
세그먼트 | 배당 수익률 |
---|---|
회사 (ALBO) | n/a |
시장 하위 25% (US) | 1.5% |
시장 상위 25% (US) | 4.7% |
업계 평균 (Biotechs) | 2.8% |
3년 후 애널리스트 예측 (ALBO) | n/a |
주목할만한 배당금: Unable to evaluate ALBO's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
고배당: Unable to evaluate ALBO's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
주주에 대한 수익 배당금
수익 보장: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
주주에 대한 현금 배당금
현금 흐름 범위: Unable to calculate sustainability of dividends as ALBO has not reported any payouts.